A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) (NCT06855771)

🧪 Interventions in This Study

• BMS-986504 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (70 Sites)

Showing the first 25 of 70 sites.

• Alaska Oncology and Hematology — Anchorage, Alaska
• Local Institution - 0099 — Boise, Idaho
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Karmanos Cancer Institute — Detroit, Michigan
• Washington University School of Medicine — St Louis, Missouri
• Memorial Sloan Kettering Cancer Center — New York, New York
• Local Institution - 0079 — Shirley, New York
• Gabrail Cancer Center — Canton, Ohio
• Providence Portland Medical Center — Portland, Oregon
• Oregon Health and Science University — Portland, Oregon
• Fred Hutchison Cancer Center — Seattle, Washington
• Medical College of Wisconsin — Milwaukee, Wisconsin
• GenesisCare - Campbelltown — Campbelltown, New South Wales
• Chris O'Brien Lifehouse — Camperdown, New South Wales
• Princess Alexandra Hospital — Woolloongabba, Queensland
• Local Institution - 0097 — Adelaide, South Australia
• Beijing Chest Hospital,Capital Medical University — Beijing, Beijing Municipality
• The First Affiliated hospital of Xiamen University — Xiamen, Fujian
• Guangxi Medical University Affiliated Tumor Hospital — Nanning, Guangxi
• The First Affiliated Hospital of Nanchang University — Nanchang, Jiangxi
• Shandong Cancer Hospital — Jinan, Shandong
• LinYi Cancer Hospital — Linyi, Shandong
• Sir Run Run Shaw Hospital of Zhejiang University School of Medicine — Hangzhou, Zhejiang
• Taizhou Hospital of Zhejiang Province — Linhai, Zhejiang
• Local Institution - 0045 — Marseille, Bouches-du-Rhône

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma, Non-Small-Cell Lung

• MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
• A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
• THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
• Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California

Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.